‘Pharma Bro’ faces more securities fraud charges

Former drug executive Martin Shkreli (pictured), who last year became a lightning rod for outrage over soaring prescription drug prices, may face additional US charges of securities fraud, a federal prosecutor says.

More charges related to Shkreli's involvement with biopharmaceutical company Retrophin Inc could be filed within a month, Assistant US Attorney Winston Paes said at a hearing in federal court in New York on Tuesday.